Hepatitis c screening in intravenuos drug users in golpayegan, isfahan through community announcement: Pilot study

Journal of Isfahan Medical School

Volumn 28, Issue SPEC. ISSUE, 2011, Pages

  Ataei, Behrooz ^a   Meshkati, Marjan ^a   Karimi, Ali ^a   Yaran, Majid ^a   Kassaian, Nazila ^a   Nokhodian, Zari ^a   Shoaei, Parisa ^a   Adibi, Peyman ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Community based announcement; Hepatitis c; Iran; Screening

Indexed keywords

HEPATITIS C ANTIBODY;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DROP IN CENTER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C VIRUS; HUMAN; INFORMATION PROCESSING; INTERVIEW; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; REHABILITATION CENTER; SCREENING TEST; SEROPREVALENCE; TRIANGULATION;

EID: 82255173815     PISSN: 10277595     EISSN: 1735854X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav 2008; 12(4 Suppl): S7-12.
2. Cocozella DR, Albuquerque MM, Borzi S, Barrio M, Dascenzo V, Santecchia JC, et al. [Prevalence of hepatic involvement, alcoholism, hepatis B, C and HIV in patients with background history of drug use]. Acta Gastroenterol Latinoam 2003; 33(4): 177-81.
3. Etard JF, Colbachini P, Dromigny JA, Perrier-Gros-Claude JD. Hepatitis C antibodies among blood donors, Senegal, 2001. Emerg Infect Dis 2003; 9(11): 1492-3.
4. Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis 2007; 13(9): 1327-31.
5. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 41-6.
6. Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect 2009; 15 Suppl 5: 10-4.
7. Farzanegan H. The prevalence of HBs Ag, HBs Ab and HBs Ab in Healthy blood donor and high risk group in Iran. Sang 1979; 73-182.
8. Loebstein R, Mahagna R, Maor Y, Kurnik D, Elbaz E, Halkin H, et al. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Isr Med Assoc J 2008; 10(11): 775-8.
9. Rahbar RA, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. International Juornal of Drug Policy 2004; 15(2): 151-5.
10. Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006; 3: 26.
11. Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol Infect 2005; 133(1): 127-36.
12. Fuglsang T, Fouchard JR, Ege PP. [Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen]. Ugeskr Laeger 2000; 162(27): 3860-4.
13. Navarro VJ, St Louis TE, Bell BP. Identification of patients with hepatitis C virus infection in New Haven County primary care practices. J Clin Gastroenterol 2003; 36(5): 431-5.